EUVIMEDEUVIMED entdecken
Crossref

Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer

Claire Thompson iD, Samuel J Withey, Nina Tunariu, Chris Parker, Alison Tree, Alison Reid, Angela Pathmanathan, Julia Murray

British Journal of Radiology · 2026

DOI: 10.1093/bjr/tqag168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, 2026. Verfasst von Claire Thompson und 7 weiteren Autor:innen. Beteiligte Einrichtung: Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, United Kingdom. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Magnetic Resonance Imaging, Whole Body Imaging. Die Arbeit nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded, with evidence supporting prostate radiotherapy in low-volume disease. However, evidence for consolidative radiotherapy to residual sites in patients rendered oligometastatic after systemic therapy is lacking. Advanced imaging with WB-MRI and PSMA PET/CT enables more accurate assessment of tumor burden and response.

Methods

This feasibility study assessed response to initial systemic treatment with an ARPI or docetaxel in 29 patients with polymetastatic (>5 metastases) HSPC. PSA and WB-MRI response using MET-RADS-P criteria were recorded.

Results

A total of 20/29 (69.0.%) of patients were down-risked to oligometastatic disease (≤5 sites) after a median of 5.5 (IQR 5-5.8) months, identified on WB-MRI. Median PSA was 0.2 ng/mL (IQR 0.1-0.7) in down-risked patients vs 1.5 ng/mL (IQR 1.1-84) in those not down-risked. Residual intraprostatic disease was seen in 55% (11/20) of down-risked patients.

Conclusions

Most patients were down-risked on WB-MRI, supporting the existence of an induced oligometastatic state and providing rationale for the STAR TRAP randomized trial (ISRCTN16448082), which will assess the role of consolidative radiotherapy in this setting. Advances in knowledge WB-MRI correlates with PSA response and shows potential as an imaging biomarker in mHSPC in this small feasibility study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMagnetic Resonance ImagingWhole Body ImagingHumansMaleFeasibility StudiesAgedDocetaxelTumor BurdenNeoplasm, ResidualNeoplasm MetastasisMiddle AgedTreatment OutcomeProstate-Specific AntigenAntineoplastic Agents

Stichwörter der Autor:innen

hormone-sensitivemetastaticprostate cancertreatment responsewhole-body MRI

Substanzen

DocetaxelProstate-Specific AntigenAntineoplastic Agents

Autor:innen und Institutionen

  • Royal Marsden NHS Foundation Trust, Sutton, SM2 5PT, United Kingdom.

ORCID-Profile: Claire Thompson

Zitieren

APA

Thompson, C., Withey, S. J., Tunariu, N., Parker, C., Tree, A., Reid, A., Pathmanathan, A., & Murray, J. (2026). Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer. British Journal of Radiology. https://doi.org/10.1093/bjr/tqag168

Vancouver

Thompson C, Withey SJ, Tunariu N, Parker C, Tree A, Reid A, et al. Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer. British Journal of Radiology. 2026. doi:10.1093/bjr/tqag168

BibTeX
@article{Thompson2026,
  author = {Thompson, Claire and Withey, Samuel J and Tunariu, Nina and Parker, Chris and Tree, Alison and Reid, Alison and Pathmanathan, Angela and Murray, Julia},
  title = {Use of whole-body MRI to evaluate residual tumor burden after initial systemic therapy in polymetastatic hormone-sensitive prostate cancer},
  journal = {British Journal of Radiology},
  year = {2026},
  doi = {10.1093/bjr/tqag168}
}
Kostenlos starten →